With a new vaccine being developed, the game of hockey could be on the verge of a new era.
With a new drug being developed for chronic traumatic encephalopathy, it’s a question of when and not if the game will get a shot.
It’s a big leap forward from when Dr. Daniel Fruin, a researcher with the University of Toronto, first developed a drug for treating concussions in the NHL.
Fruus first developed the drug, TBI-01, in 2012, but had it tested on himself before the league approved it for the first time.
“We got tested, and we didn’t have any signs of concussion symptoms,” Fruins brother, Dr. Dan, told NHL.com.
“Then we had to get another one and it was all good.
I think there’s a lot of good news there.”
While the new drug, called SleepMed, has been tested on NHL players, its effectiveness in the regular season is still in question.
The NHL has been unable to test its own sleep medicine, the SleepGem, on any of its players, and even when it has tested, the drug has shown no effect on the players.
But Dr. David Ebersol, the director of the Neuropsychopharmacology Center at Johns Hopkins University and a co-author of the SleepMed study, said that the results could be misleading.
“If you’re going to do the drug in a trial, then you have to show that you’re doing the drug well,” Ebersoll said.
“And we’ve not seen that.”
Dr. Ebersols co-authored a paper last year that looked at whether the Sleep meds could reduce the risk of dementia, the main type of dementia associated with head injuries.
His team also looked at how the Sleep Meds could help treat players suffering from concussion symptoms.
The results were published last week in the journal JAMA Psychiatry.
The team also found that the drug didn’t significantly reduce the amount of time that players were on their own in their sleep.
“I don’t think there is anything particularly novel about this work,” Ebertsol said.
“You’re talking about a drug that has been shown to have an effect, that’s been studied in a controlled setting and not tested in a clinical setting.”
SleepMed is not the only sleep medicine being developed.
The National Institutes of Health (NIH) is also looking into an improved sleep aid called ZMA that’s designed to help athletes keep their bodies asleep.
But it’s not clear if either drug will have a significant impact on the game.
The latest data on sleep has been released in two studies.
One study, which was published in March in the Journal of Clinical Endocrinology & Metabolism, compared the effectiveness of a SleepMed and ZMA drug for people who had concussion symptoms and were awake.
SleepMed improved sleep quality, but ZMA did not, suggesting that the Sleep Medicine would be ineffective for players with concussion symptoms who weren’t awake.
A second study, published in April in the American Journal of Psychiatry, compared sleep and cognitive function of former NHL players who had experienced concussion and were not awake in a study that included the Sleep-Gem drug.
The SleepGems drug improved sleep but Zma did not.
The SleepMed drug didn://bit.ly/1u2yB9lSleepMed and the Sleep medicine are both being developed by NeuroMed Therapeutics, a company owned by Eli Lilly, which is known for its expertise in treating pain and neurodegenerative diseases.
The company’s chief executive, Jeffrey Daim, was a former vice president at the National Institutes for Health (NIR) and the National Science Foundation.
The drug was tested in the NCAA tournament and NHL All-Star games.
In the NCAA, SleepMed was tested on both teams.
Sleep Med and Zma are both approved for use in the NBA and Major League Soccer.